Correction

Combination of T-Cell Bispecific Antibodies With PD-L1 Checkpoint Inhibition Elicits Superior Anti-Tumor Activity (vol 10, 575737, 2020)

Journal

FRONTIERS IN ONCOLOGY
Volume 11, Issue -, Pages -

Publisher

FRONTIERS MEDIA SA
DOI: 10.3389/fonc.2021.650149

Keywords

solid tumors; immunotherapy; T-cell bispecific antibody; carcinoembryonic antigen T-cell bispecific antibody; programmed death– ligand 1; combination; humanized mice

Categories

Funding

  1. F Hoffmann-La Roche Ltd.

Ask authors/readers for more resources

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Recommended

No Data Available
No Data Available